Compare PLPC & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PLPC | PHAR |
|---|---|---|
| Founded | 1947 | 1988 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Water Sewer Pipeline Comm & Power Line Construction | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.1B |
| IPO Year | N/A | N/A |
| Metric | PLPC | PHAR |
|---|---|---|
| Price | $228.89 | $16.81 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $38.00 |
| AVG Volume (30 Days) | ★ 88.2K | 27.8K |
| Earning Date | 10-29-2025 | 11-06-2025 |
| Dividend Yield | ★ 0.37% | N/A |
| EPS Growth | ★ 13.62 | N/A |
| EPS | ★ 7.55 | 0.00 |
| Revenue | ★ $663,346,000.00 | $362,274,000.00 |
| Revenue This Year | $16.31 | $25.19 |
| Revenue Next Year | $13.74 | $4.47 |
| P/E Ratio | ★ $29.85 | $2,998.75 |
| Revenue Growth | 15.93 | ★ 26.78 |
| 52 Week Low | $118.99 | $7.50 |
| 52 Week High | $245.99 | $18.30 |
| Indicator | PLPC | PHAR |
|---|---|---|
| Relative Strength Index (RSI) | 62.92 | 50.62 |
| Support Level | $206.34 | $16.61 |
| Resistance Level | $223.14 | $17.37 |
| Average True Range (ATR) | 8.82 | 0.70 |
| MACD | 0.74 | -0.09 |
| Stochastic Oscillator | 99.93 | 38.17 |
Preformed Line Products Co is a designer and manufacturer of products and systems for constructing and maintaining overhead and underground networks for energy, telecommunication, cable operators, data communication, and other industries. In addition, it provides solar hardware systems and mounting hardware for a variety of solar power applications. Its products consist of Energy Products, Communications Products, and Special Industries Products. The company's majority of the revenue is derived from the sale of products in The Americas with operations also in PLP-USA, Europe, the Middle East and Africa, and Asia-Pacific. The revenue gets driven by Energy products which comprise protecting transmission conductors, spacers, spacer-dampers, and Stockbridge dampers.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.